Get started
Work

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : résultats à 2 ans de RELATIVITY-047

Year: 2023
Type: article
DOI: 10.1016/j.fander.2023.09.600
Authors: H.A. Tawbi, S. Hodi, E.J. Lipson, D. Schadendorf, P.A. Ascierto, L. Matamala, E. Castillo Gutiérrez, P. Rutkowski, H. Gogas, C.D. Lao, J.J. De Menezes, S. Dalle, A. Arance, J.J. Grob, B. Ratto, S. Rodriguez, Y. Xu, P. Wang, S. Dolfi, G. Long
Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Deutsches Konsortium für Translationale Krebsforschung, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Fundación Arturo López Pérez, Instituto Nacional del Cáncer, The Maria Sklodowska-Curie National Research Institute of Oncology, National and Kapodistrian University of Athens, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, Hospices Civils de Lyon, Hospital Clínic de Barcelona, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Bristol-Myers Squibb (United States), The University of Sydney, Melanoma Institute Australia
Language: French
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4388760170
FWCI:
Cites:
Cited by:
Related to: 10